Immuno-polymeric Drugs For Prostate Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$626,995.00
Summary
Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.
Characterisation Of Two Novel Markers Of Osteosarcoma Metastasis As Potential Therapeutic Targets
Funder
National Health and Medical Research Council
Funding Amount
$624,500.00
Summary
Osteosarcoma (OS) is the most common bone tumour in children and adolescents. In spite of aggressive chemotherapy, OS tumours that metastasise to the lungs result in dismal long-term survivals of only 10-20%. For these patients, new treatment options are desperately needed. In this proposal we show compelling data identifying two new markers of OS metastasis. This research aims to validate the suitability of these novel markers as therapeutic targets to prevent OS metastasis.
Development Of A Novel Drug For Chronic And Infected Wounds
Funder
National Health and Medical Research Council
Funding Amount
$482,362.00
Summary
Chronic wounds affect more than 9 million people worldwide and demand for wound care is increasing. The annual cost to healthcare systems in the US and Australia in treating such wounds is US$25 billion and AU$3 billion, respectively, and there is urgent need for more effective approaches.
Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
An Investigation Of The Involvement Of Clotting Factors In Abdominal Aortic Aneurysm (AAA) Progression Within A Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$189,401.00
Summary
Early stage weakening of the main abdominal artery is present in ~100,000 Australians and currently has no accepted therapy. Development of drug therapies which limit progression of the weakening process is urgently needed. In this study involvement of the clotting cascade in artery weakening will be investigated. The study have been planned in order to identify new strategies which can be developed as treatments for artery weakening in patients.
KLK4 Is A Master Regulator Of Tumour Microenvironment Remodelling In Prostate Cancer And Bone Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$596,305.00
Summary
The current biomarker for prostate cancer, PSA, belongs to a large family of related proteins called KLK enzymes. We have evidence that one of these enzymes, KLK4, regulates many different pathways involved in tumour spreading especially to bones. This project will determine the specific components involved with a view to finding better biomarkers of tumour spread and bone metastasis and designing better treatments for these aspects of the disease.
Promoting Activity For Frail Aged In Post-acute Hospital Settings: A Randomised Controlled Trial Of Accelerometry
Funder
National Health and Medical Research Council
Funding Amount
$542,119.00
Summary
Keeping older people in hospital actively mobile is a vital objective of high quality aged care. Using accelerometers, the Centre for Research in Geriatric Medicine at the University of Queensland, and its partner, the CSIRO e-health Research Centre, are trialing a method of promoting activity in older rehabilitation patients. Potentially, a system of _activity management� could solve an age old problem in hospital care of older people.
Characterisation and improvement of radiation beams used for radiotherapy of small lesions. This project aims to characterise the radiation dose from a medical linear accelerator after the beam has been shaped by a mini-multileaf collimator. The characterisation will be achieved through a combination of computer simulations and experimental investigation of the beam using the technique of three-dimensional gel dosimetry. When the dosage characteristics are known, techniques will be developed to ....Characterisation and improvement of radiation beams used for radiotherapy of small lesions. This project aims to characterise the radiation dose from a medical linear accelerator after the beam has been shaped by a mini-multileaf collimator. The characterisation will be achieved through a combination of computer simulations and experimental investigation of the beam using the technique of three-dimensional gel dosimetry. When the dosage characteristics are known, techniques will be developed to improve radiotherapy treatments in patients with small lesions with sizes of up to a few centimetres. This will lead to an improved outcome for some cancer patients.Read moreRead less
Development of therapeutic agents that target carbonic anhydrase enzymes. This research will discover new chemical entities (compounds) that may lead to therapies for the treatment of cancer, glaucoma and malaria. The research underpins a mechanism to add value to our compounds before partnering with industry to transform the discoveries made here to deliverable therapies that could benefit the health of millions, thus offering a potentially high value contribution to the Australian economy. The ....Development of therapeutic agents that target carbonic anhydrase enzymes. This research will discover new chemical entities (compounds) that may lead to therapies for the treatment of cancer, glaucoma and malaria. The research underpins a mechanism to add value to our compounds before partnering with industry to transform the discoveries made here to deliverable therapies that could benefit the health of millions, thus offering a potentially high value contribution to the Australian economy. The experience and commitment of the multi-disciplinary network of researchers offers exceptional training and employment opportunities for tomorrow's scientists in techniques for discovery and characterisation of novel chemicals, and their interaction with disease targets.Read moreRead less
Early Career Industry Fellowships - Grant ID: IE230100441
Funder
Australian Research Council
Funding Amount
$474,443.00
Summary
Sounds of change: using ecological knowledge to advance acoustic monitoring. To recover biodiversity, conservation actions must be informed by robust ecological data. In partnership with Bush Heritage Australia, this project aims to transform ecological monitoring with eco-acoustic technologies by developing new acoustic metrics to measure biodiversity at various levels, from individual species through to whole communities. This project will combine advanced computer methods with theories of ani ....Sounds of change: using ecological knowledge to advance acoustic monitoring. To recover biodiversity, conservation actions must be informed by robust ecological data. In partnership with Bush Heritage Australia, this project aims to transform ecological monitoring with eco-acoustic technologies by developing new acoustic metrics to measure biodiversity at various levels, from individual species through to whole communities. This project will combine advanced computer methods with theories of animal sounds and communities to generate metrics that are informed by animal ecology and directly address monitoring needs of conservation organisations. By experimentally testing the metrics on long-duration real-world sound data, this project will provide new tools to measure conservation impact and prioritise actions.Read moreRead less